If this is your first visit, be sure to check out the FAQ in HCMA Announcements. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. Your Participation in this message board is strictly voluntary. Information and comments on the message board do not necessarily reflect the feelings, opinions, or positions of the Hypertrophic Cardiomyopathy Association. At no time should participants to this board substitute information within for individual medical advice. The Hypertrophic Cardiomyopathy Association shall not be liable for any information provided herein. All participants in this board should conduct themselves in a professional and respectful manner. Failure to do so will result in suspension or termination. The moderators of the message board working with the HCMA will be responsible for notifying participants if they have violated the rules of conduct for the board. Moderators or HCMA staff may edit any post to ensure it conforms with the rules of the board or may delete it. This community is welcoming to all those with HCM we ask that you remember each user comes to the board with information and a point of view that may differ from that which you hold, respect is critical, please post respectfully. Thank you


No announcement yet.



About the Author


Barely Heart
Find out more about purple_ness1
  • Filter
  • Time
  • Show
Clear All
new posts

  • heya

    well i was watch tv and they said sumthink about this device or sumthink ,sum new thing has any one heard of it ?? and would it help pll with hcm ??
    the artcal below

    World First C-Pulse Heart Failure Device
    Monday, 9 May 2005, 3:18 pm
    Press Release: Auckland District Health Board
    World First C-Pulse Heart Failure Device
    For immediate release Monday 9 May 2005


    Patient in long term heart failure receives new hope through C-Pulse heart failure device

    A 56-year old New Zealand man has become the first person to be implanted with the C-Pulse heart device developed by Australian company Sunshine Heart, Inc.

    The world first operation took place at Auckland City Hospital on 4th May with doctors today releasing details of the successful implantation.

    The operation went smoothly, the device is working well, and the patient is recovering quickly with good improvement in heart performance. The implant took 2.5 hours, and was done without using a heart-lung bypass machine or stopping the heart.

    “This patient had suffered heart failure for 9 years and had a very limited quality of life. He had been hospitalized on 6 occasions in the last 18 months,” said Dr Paget Milsom, Head of Cardiothoracic Surgery at Auckland City Hospital.

    “C-Pulse therapy was considered the best option to improve the life of this patient. We are delighted to be able to offer this patient a device that is quite unlike anything previously used for the treatment of heart failure. Following the surgery, the device is working well and the patient is showing augmentation of his native heart function.”

    The Sunshine Heart C-Pulse is an implantable, non-blood contacting mechanical heart assist device powered by an external driver unit. The C-Pulse works to reduce the load on the heart and to assist the heart to pump blood.

    “The successful world-first implantation of the non-blood contacting heart-assist C-Pulse represents a medical milestone and heralds a paradigm shift in the approach to mechanical circulatory support. It is also a key milestone for the company,” said CEO of Sunshine Heart, Inc, Mr. Donald Rohrbaugh.

    “The treatment options for people in this category of heart failure are limited, so there is a real need for a device such as the C-Pulse. The supply of donor hearts for transplantation is well below the number needed and only about 30% of patients are suitable for heart failure treatment with a pacemaker that can help to correct the pumping rhythm of the failing heart,” added Dr William Peters MD, Clinical Research Fellow in Cardiothoracic Surgery at Auckland City Hospital and Medical Director of Sunshine Heart.

    “Follow-up measurements of quality of life and heart function will be completed in this patient at 3 and 6 months. Up to 10 patients will be enrolled in the study. Additional study centres are expected to be opened at leading hospitals in Australia in the future,” Dr Peters said.

    Heart failure is a progressively worsening condition characterized by shortness of breath with mild exercise, fatigue, dizziness and fluid retention. Its cause is the inability of the heart to pump sufficient blood around the body to meet its oxygen requirement.

    It has been estimated that 325,000 people in Australia have symptomatic heart failure, and that there are 22,000 admissions to hospital for heart failure each year. Heart failure is believed to contribute to over 1.4 million days of hospitalization annually at a cost of more than $1B. In excess of 5 million people in the USA have heart failure.

    Avoiding blood contact makes C-Pulse implantation less complex and less costly when compared to most other blood-contacting heart pumps, and reduces the risks of bleeding complications. Avoiding blood contact also allows the C-Pulse device to be safely turned on and off.

    The C-Pulse has three main components:

    * A cuff which consists of a wrap and a balloon. The cuff is secured around the ascending aorta (the main blood vessel carrying blood from the heart to the body). The balloon is inflated and deflated in time with the heart rhythm to improve blood supply to the body and to the heart muscle itself, as well as reducing the work load of the heart.

    * A sensing lead which conveys the heart's electrical signals to the driver unit

    * A wearable driver unit which is linked by an air tube to the cuff and which causes the balloon in the cuff to inflate and deflate in rhythm with the heart

    The C-Pulse is unique as compared with other heart assist devices currently on the market such as the Left Ventricular Assist Devices (LVADs). It is the only device that does not come into direct contact with the blood and it requires a less invasive surgical procedure. It is also non-obligatory, meaning that if its function is interrupted, the situation is not life-threatening and the patient is much less likely to have an adverse reaction than if an LVAD failed.

    Forever Young

    I was diagnosedwith HCM at 6.
    Went into Atrial fibrillation so had a ICD put in at 16
    Went into Heart failure at 17
    Got a heart transplant at 21(2009)

  • #2

    Hi there Margie. Good to see another post from you.

    I saw the TV news item tonight too and wondered about the HOCM connection.

    I've found the transcript from the broadcast. (see below). It says that the patient concerned has cardiomyopathy, but doesn't say what sort.

    The big advantage it would seem is that it doesn't require an operation which opens the heart itself.

    A heart failure patient is recovering in hospital after world-first surgery to implant an Australian-designed device which helps the heart pump blood.

    The 56-year-old New Zealand man, who'd had heart failure for almost a decade but was deemed unsuitable for a transplant, received the device during a two and a half hour operation at Auckland City Hospital on Wednesday.

    "He's up on his feet and moving around," said William Peters, the hospital's clinical research fellow in cardiothoracic surgery.

    "His heart is definitely being well assisted by the device. It's like a little turbo booster on top of the heart."

    Peters, who designed the C-pulse heart device with surgeon Paget Milsom, said without the operation, the patient had a very poor quality of life and a reduced life expectancy.

    "He was on optimum medication already," Peters said.

    "He'd recently been in and out of hospital a lot and hadn't been able to work for a number of years.

    "He really didn't have any other option other than to suffer along as he was.

    "It's really thrilling to see him responding well to the device."

    Peters said the key component of the device, developed by Australian company Sunshine Heart Incorporated, was a balloon cuff, similar to a blood pressure cuff, which was wrapped around the patient's aorta.

    A sensing wire picks up the heart's electrical signals, allowing the device to time the inflation and deflation of the balloon to the heart beat.

    The balloon helps the aorta pump blood to the body, reducing the heart's workload.

    A wearable unit driving the device works on rechargeable batteries and a home unit is also available which can be plugged into an electricity outlet.

    Peters said the device was designed to be turned off occasionally without affecting the patient.

    "While we want it to run most of the time to unload the heart, it's safe and expected to be able to turn the device off and disconnect it if you want to have a shower, for example," he said.

    "If it fails, the balloon will just collapse and deflate. The heart and the blood vessels are all in their natural state and just carry on as they would."

    Peters said unlike other heart pumps, the C-pulse avoided blood contact, reducing the risk of blood clots.

    He first came up with the idea while working at Melbourne's Alfred Hospital, later co-founding Sunshine Heart with Sydney businessman Crispin Marsh.

    The company, which received an Australian Government startup grant, is listed on the Australian stock exchange.

    Peters said a non-randomised pilot study of 10 people implanted with the device was planned, using patients in Australia and New Zealand.

    He said patients with moderate heart failure, aged 18 to 80, would be eligible for the implant.

    "The important thing is to follow the patients over the long term to ensure there are no significant risks," Dr Peters said.

    Eventually, a larger randomised study would be carried out, possibly in the United States, to facilitate full market approval.

    An estimated 325,000 Australians have heart failure in varying degrees.

    Peters said about half of those were due to heart attacks, while another 50 per cent were either caused by a virus or there was no known reason.

    The Auckland man who agreed to be the device's first recipient suffers cardiomyopathy, a disease affecting the function of the heart.

    He's expected to be released from hospital in five days.


    • #3
      Thank you for sharing this information.

      Isn't technology a grand thing?? In the future if successfull it should prove to help so many who have reached "burn out phase " or end stage heart failure. I have read that in some the left ventricular assist devises have allowed some to stabilize enough to notneed a transplant. If this works it sounds even better for those so unfortunate to have such poor quality of life.

      Dx @ 47 with HOCM & HF:11/00
      Guidant ICD:Mar.01, Recalled/replaced:6/05 w/ Medtronic device
      Lead failure,replaced 12/06.
      SF lead recall:07,extracted leads and new device 2012
      [email protected] Tufts, Boston:10/5/03; age 50. ( [email protected] 240 mmHg ++)
      Paroxysmal A-Fib: 06-07,2010 controlled w/sotalol dosing
      Genetic mutation 4/09, mother(d), brother, son, gene+
      Mother of 3, grandma of 3:Tim,27,Sarah,33w/6 y/o old Sophia, 5 y/o Jack, Laura 34, w/ 5 y/o old Benjamin


      Today's Birthdays